O	0	6	Double
O	6	7	-
O	7	12	blind
O	12	13	,
O	14	24	randomized
O	25	32	placebo
O	33	43	controlled
O	44	49	trial
O	50	52	of
B-intervention	53	64	fulvestrant
O	65	73	compared
O	74	78	with
B-control	79	89	exemestane
O	90	95	after
O	96	101	prior
O	102	114	nonsteroidal
O	115	124	aromatase
O	125	134	inhibitor
O	135	142	therapy
O	143	145	in
O	146	160	postmenopausal
O	161	166	women
O	167	171	with
O	172	179	hormone
O	180	188	receptor
O	188	189	-
O	189	197	positive
O	197	198	,
O	199	207	advanced
O	208	214	breast
O	215	221	cancer
O	221	222	:
O	223	230	results
O	231	235	from
O	236	241	EFECT
O	241	242	.

O	243	246	The
O	247	252	third
O	252	253	-
O	253	263	generation
O	264	276	nonsteroidal
O	277	286	aromatase
O	287	297	inhibitors
O	298	299	(
O	299	302	AIs
O	302	303	)
O	304	307	are
O	308	320	increasingly
O	321	325	used
O	326	328	as
O	329	337	adjuvant
O	338	341	and
O	342	347	first
O	347	348	-
O	348	352	line
O	353	361	advanced
O	362	369	therapy
O	370	373	for
O	374	388	postmenopausal
O	388	389	,
O	390	397	hormone
O	398	406	receptor
O	406	407	-
O	407	415	positive
O	416	417	(
O	417	419	HR
O	419	420	+
O	420	421	)
O	422	428	breast
O	429	435	cancer
O	435	436	.

O	437	444	Because
O	445	449	many
O	450	458	patients
O	459	471	subsequently
O	472	482	experience
O	483	494	progression
O	495	497	or
O	498	505	relapse
O	505	506	,
O	507	509	it
O	510	512	is
O	513	522	important
O	523	525	to
O	526	534	identify
O	535	541	agents
O	542	546	with
O	547	555	efficacy
O	556	561	after
O	562	564	AI
O	565	572	failure
O	572	573	.

O	574	584	Evaluation
O	585	587	of
O	588	596	Faslodex
O	597	603	versus
O	604	614	Exemestane
O	615	623	Clinical
O	624	629	Trial
O	630	631	(
O	631	636	EFECT
O	636	637	)
O	638	640	is
O	641	642	a
O	643	653	randomized
O	653	654	,
O	655	661	double
O	661	662	-
O	662	667	blind
O	667	668	,
O	669	676	placebo
O	677	687	controlled
O	687	688	,
O	689	700	multicenter
O	701	706	phase
O	707	710	III
O	711	716	trial
O	717	719	of
O	720	731	fulvestrant
O	732	738	versus
O	739	749	exemestane
O	750	752	in
O	753	767	postmenopausal
O	768	773	women
O	774	778	with
O	779	781	HR
O	781	782	+
O	783	791	advanced
O	792	798	breast
O	799	805	cancer
O	806	807	(
O	807	810	ABC
O	810	811	)
O	812	823	progressing
O	824	826	or
O	827	836	recurring
O	837	842	after
O	843	855	nonsteroidal
O	856	858	AI
O	858	859	.

O	860	863	The
O	864	871	primary
O	872	875	end
O	876	881	point
O	882	885	was
B-outcome-Measure	886	890	time
I-outcome-Measure	891	893	to
I-outcome-Measure	894	905	progression
I-outcome-Measure	906	907	(
I-outcome-Measure	907	910	TTP
I-outcome-Measure	910	911	)
O	911	912	.

O	913	914	A
O	915	926	fulvestrant
O	927	934	loading
O	934	935	-
O	935	939	dose
O	940	941	(
O	941	943	LD
O	943	944	)
O	945	952	regimen
O	953	956	was
O	957	961	used
O	961	962	:
O	963	966	500
O	967	969	mg
O	970	985	intramuscularly
O	986	988	on
O	989	992	day
O	993	994	0
O	994	995	,
O	996	999	250
O	1000	1002	mg
O	1003	1005	on
O	1006	1010	days
O	1011	1013	14
O	1013	1014	,
O	1015	1017	28
O	1017	1018	,
O	1019	1022	and
O	1023	1026	250
O	1027	1029	mg
O	1030	1035	every
O	1036	1038	28
O	1039	1043	days
O	1044	1054	thereafter
O	1054	1055	.

O	1056	1066	Exemestane
O	1067	1069	25
O	1070	1072	mg
O	1073	1079	orally
O	1080	1083	was
O	1084	1096	administered
O	1097	1101	once
O	1102	1107	daily
O	1107	1108	.

O	1109	1110	A
O	1111	1116	total
O	1117	1119	of
B-total-participants	1120	1123	693
O	1124	1129	women
O	1130	1134	were
O	1135	1143	randomly
O	1144	1152	assigned
O	1153	1155	to
O	1156	1167	fulvestrant
O	1168	1169	(
O	1169	1170	n
O	1171	1172	=
B-intervention-participants	1173	1176	351
O	1176	1177	)
O	1178	1180	or
O	1181	1191	exemestane
O	1192	1193	(
O	1193	1194	n
O	1195	1196	=
B-control-participants	1197	1200	342
O	1200	1201	)
O	1201	1202	.

O	1203	1216	Approximately
O	1217	1219	60
O	1219	1220	%
O	1221	1223	of
O	1224	1232	patients
O	1233	1236	had
O	1237	1245	received
O	1246	1248	at
O	1249	1254	least
O	1255	1258	two
O	1259	1264	prior
O	1265	1274	endocrine
O	1275	1284	therapies
O	1284	1285	.

B-outcome	1286	1292	Median
I-outcome	1293	1296	TTP
O	1297	1300	was
B-iv-cont-median	1301	1302	3
I-iv-cont-median	1302	1303	.
I-iv-cont-median	1303	1304	7
I-iv-cont-median	1305	1311	months
O	1312	1314	in
O	1315	1319	both
O	1320	1326	groups
O	1327	1328	(
O	1328	1334	hazard
O	1335	1340	ratio
O	1341	1342	=
O	1343	1344	0
O	1344	1345	.
O	1345	1348	963
O	1348	1349	;
O	1350	1352	95
O	1352	1353	%
O	1354	1356	CI
O	1356	1357	,
O	1358	1359	0
O	1359	1360	.
O	1360	1363	819
O	1364	1366	to
O	1367	1368	1
O	1368	1369	.
O	1369	1372	133
O	1372	1373	;
O	1374	1375	P
O	1376	1377	=
O	1378	1379	.
O	1379	1383	6531
O	1383	1384	)
O	1384	1385	.

O	1386	1389	The
B-outcome	1390	1397	overall
I-outcome	1398	1406	response
I-outcome	1407	1411	rate
O	1412	1413	(
B-iv-bin-percent	1413	1414	7
I-iv-bin-percent	1414	1415	.
I-iv-bin-percent	1415	1416	4
I-iv-bin-percent	1416	1417	%
O	1418	1419	v
B-cv-bin-percent	1420	1421	6
I-cv-bin-percent	1421	1422	.
I-cv-bin-percent	1422	1423	7
I-cv-bin-percent	1423	1424	%
O	1424	1425	;
O	1426	1427	P
O	1428	1429	=
O	1430	1431	.
O	1431	1434	736
O	1434	1435	)
O	1436	1439	and
B-outcome	1440	1448	clinical
I-outcome	1449	1456	benefit
I-outcome	1457	1461	rate
O	1462	1463	(
B-iv-bin-percent	1463	1465	32
I-iv-bin-percent	1465	1466	.
I-iv-bin-percent	1466	1467	2
I-iv-bin-percent	1467	1468	%
O	1469	1470	v
B-cv-bin-percent	1471	1473	31
I-cv-bin-percent	1473	1474	.
I-cv-bin-percent	1474	1475	5
I-cv-bin-percent	1475	1476	%
O	1476	1477	;
O	1478	1479	P
O	1480	1481	=
O	1482	1483	.
O	1483	1486	853
O	1486	1487	)
O	1488	1492	were
O	1493	1500	similar
O	1501	1508	between
O	1509	1520	fulvestrant
O	1521	1524	and
O	1525	1535	exemestane
O	1536	1548	respectively
O	1548	1549	.

B-outcome	1550	1556	Median
I-outcome	1557	1565	duration
I-outcome	1566	1568	of
I-outcome	1569	1577	clinical
I-outcome	1578	1585	benefit
O	1586	1589	was
B-iv-cont-median	1590	1591	9
I-iv-cont-median	1591	1592	.
I-iv-cont-median	1592	1593	3
O	1594	1597	and
B-cv-cont-median	1598	1599	8
I-cv-cont-median	1599	1600	.
I-cv-cont-median	1600	1601	3
I-cv-cont-median	1602	1608	months
O	1608	1609	,
O	1610	1622	respectively
O	1622	1623	.

O	1624	1628	Both
O	1629	1639	treatments
O	1640	1644	were
B-outcome	1645	1649	well
I-outcome	1650	1659	tolerated
O	1659	1660	,
O	1661	1665	with
O	1666	1668	no
O	1669	1680	significant
O	1681	1692	differences
O	1693	1695	in
O	1696	1699	the
B-outcome	1700	1709	incidence
I-outcome	1710	1712	of
I-outcome	1713	1720	adverse
I-outcome	1721	1727	events
I-outcome	1728	1730	or
I-outcome	1731	1738	quality
I-outcome	1739	1741	of
I-outcome	1742	1746	life
O	1746	1747	.

O	1748	1763	Pharmacokinetic
O	1764	1768	data
O	1769	1776	confirm
O	1777	1781	that
O	1782	1788	steady
O	1788	1789	-
O	1789	1794	state
O	1795	1798	was
O	1799	1806	reached
O	1807	1813	within
O	1814	1815	1
O	1816	1821	month
O	1822	1826	with
O	1827	1830	the
O	1831	1833	LD
O	1834	1842	schedule
O	1843	1845	of
O	1846	1857	fulvestrant
O	1857	1858	.

O	1859	1870	Fulvestrant
O	1871	1873	LD
O	1874	1877	and
O	1878	1888	exemestane
O	1889	1892	are
O	1893	1900	equally
O	1901	1907	active
O	1908	1911	and
O	1912	1916	well
O	1916	1917	-
O	1917	1926	tolerated
O	1927	1929	in
O	1930	1931	a
O	1932	1942	meaningful
O	1943	1953	proportion
O	1954	1956	of
O	1957	1971	postmenopausal
O	1972	1977	women
O	1978	1982	with
O	1983	1986	ABC
O	1987	1990	who
O	1991	1995	have
O	1996	2007	experienced
O	2008	2019	progression
O	2020	2022	or
O	2023	2033	recurrence
O	2034	2040	during
O	2041	2050	treatment
O	2051	2055	with
O	2056	2057	a
O	2058	2070	nonsteroidal
O	2071	2073	AI
O	2073	2074	.
